Natco Pharma Limited provide legal update on Ibrutinib

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced that a US District Court has issued a decision in favour of Pharmacyclics (a subsidiary of AbbVie), the brand owner of Imbruvica® in a PIV litigation involving the product.

NATCO and its marketing partner in US for the product, Alvogen Pine Brook LLC, USA, shall review the judgement and evaluate all options to appeal the judgement. We believe that we have a strong case and will continue to defend vigorously.

In the year 2018 NATCO and Alvogen, have filed an Abbreviated New Drug Application (ANDA) with PIV certification for generic version of the product.

Shares of Natco Pharma Ltd. was last trading in BSE at Rs. 965.5 as compared to the previous close of Rs. 967. The total number of shares traded during the day was 9045 in over 978 trades.

The stock hit an intraday high of Rs. 973.95 and intraday low of 957.25. The net turnover during the day was Rs. 8728075.

*All brand names and trademarks are the property of their respective owners

Source : Equity Bulls

Keywords